Watch Live

Tweet TWEET

PharMerica Corporation Names Patrick G. LePore to Its Board of Directors

  PharMerica Corporation Names Patrick G. LePore to Its Board of Directors

Business Wire

LOUISVILLE, Ky. -- January 14, 2013

PharMerica Corporation (NYSE: PMC), a national provider of institutional
pharmacy, specialty infusion and hospital pharmacy management services, today
announced that it has appointed Patrick G. LePore to the Company’s Board of
Directors.

Since 2007, Mr. LePore has served as the Chairman of the Board of Par
Pharmaceutical Companies, Inc., where he also served as Chief Executive
Officer until the company’s acquisition by private equity investor TPG in
September 2012. Prior to joining Par Pharmaceutical, he was President of
Cardinal Health, Inc.’s healthcare marketing group. Mr. LePore is a trustee of
Villanova University, where he earned a B.A. degree. Mr. LePore earned his MBA
degree from Fairleigh Dickinson University.

Commenting on the addition of Mr. LePore to the Board, Geoffrey G. Meyers,
PharMerica’s Chairman of the Board, said, “Mr. LePore is an excellent addition
to our Board. His management experience in the pharmaceutical industry brings
considerable value to our company, and we look forward to his insight and
contributions.”

About PharMerica

PharMerica Corporation is a leading institutional pharmacy, specialty infusion
and hospital pharmacy management services company servicing healthcare
facilities in the United States. PharMerica operates pharmacies in 45 states.
PharMerica’s customers are institutional healthcare providers, such as nursing
centers, assisted living facilities, hospitals and other long-term care
providers. In addition, the Company provides specialty infusion
pharmaceuticals to patients in a home setting. The Company also provides
pharmacy management services to long-term care hospitals.

Forward-looking Statements

This press release contains “forward-looking statements” within the meaning of
Section27A of the Securities Act of 1933, as amended, and Section21E of the
Securities Exchange Act of 1934, as amended, which reflect the Company’s
current estimates, expectations and projections about its future results,
performance, prospects and opportunities. Forward-looking statements include
statements that are not historical facts and can be identified by
forward-looking words such as “anticipate,” “believe,” “could,” “estimate,”
“expect,” “intend,” “plan,” “may,” “should,” “will,” “would,” “project” and
similar expressions. These forward-looking statements are based upon
information currently available to us and are subject to a number of risks,
uncertainties and other factors that could cause the Company’s actual results,
performance, prospects or opportunities to differ materially from those
expressed in, or implied by, these forward-looking statements. Important
factors that could cause the Company’s actual results to differ materially
from the results referred to in the forward-looking statements we make in this
press release are included in the Risk Factors section set forth in the
Company’s Annual Report on Form 10-K filed with the SEC and in other reports,
including Quarterly Reports on Form 10-Q filed with the SEC by the Company.

You are cautioned not to place undue reliance on any forward-looking
statements, all of which speak only as of the date of this press release.
Except as required by law, we undertake no obligation to publicly update or
release any revisions to these forward-looking statements to reflect any
events or circumstances after the date of this press release or to reflect the
occurrence of unanticipated events. All subsequent written and oral
forward-looking statements attributable to us or any person acting on the
Company’s behalf are expressly qualified in their entirety by the cautionary
statements contained or referred to in this press release and in the Risk
Factors section set forth in the Company’s Annual Report on Form 10-K filed
with the SEC and in other reports filed with the SEC by the Company.

Contact:

PharMerica Corporation
Michael J. Culotta, 502-627-7475
Executive Vice President and Chief Financial Officer
 
Press spacebar to pause and continue. Press esc to stop.